Nitin Bhasin, MD
Nephrology · San Dimas, CANPI 1669790838
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,841 of the $6,883 with a category attached, or 84.9%. It is spread thinly across 24 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,141 and has fallen 60.9% since, to $838 in 2025.
Across 247 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$1K
- AstraZeneca$1K
- Akebia Therapeutics Inc$637
- Amgen$623
- Otsuka America Pharmaceutical, Inc.$575
- Mallinckrodt Hospital Products Inc.$381
- plus $2K from 18 others
Across 79 payments — averaging $12,271 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$485K
- Bayer$291K
- Boehringer Ingelheim$118K
- AstraZeneca$41K
- Merck$34K
- Boehringer Ingelheim International GmbH$26
What the payments were for
- Travel & lodging$91113%
- Food & beverage$5,84185%
- Education$1312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 12 | $1,395 |
| AstraZeneca(2 entities) | 50 | $1,183 |
| Akebia Therapeutics Inc | 32 | $637 |
| Amgen(2 entities) | 26 | $623 |
| Otsuka America Pharmaceutical, Inc. | 26 | $575 |
| Mallinckrodt Hospital Products Inc. | 16 | $381 |
| Calliditas Therapeutics US Inc. | 14 | $335 |
| Fresenius USA Marketing, Inc. | 14 | $242 |
| GSK | 9 | $228 |
| Aurinia Pharma U.S., Inc. | 5 | $223 |
| Vifor Pharma, Inc. | 8 | $221 |
| Novo Nordisk | 6 | $123 |
| Mallinckrodt Enterprises LLC | 4 | $122 |
| Novartis | 3 | $111 |
| Ultragenyx Pharmaceutical Inc. | 6 | $111 |
| Travere Therapeutics, Inc. | 3 | $95 |
| OPKO Pharmaceuticals, LLC | 4 | $64 |
| Cormedix Inc. | 2 | $55 |
| Boehringer Ingelheim | 2 | $42 |
| Gilead | 1 | $32 |
| Boston Scientific | 1 | $26 |
| Sanofi | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| CSL Behring | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,883 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 45 | $31,280 |
| VelphoroSucroferric Oxyhydroxide | 11 | $16,995 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 18 | $1,485 |
| Labetalol Hcl | 15 | $1,388 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $999 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $964 |
| Nifedipine ErNifedipine | 21 | $443 |
| Furosemide | 74 | $278 |
| Calcitriol | 20 | $227 |
| Donepezil Hcl | 13 | $172 |
| Lisinopril | 25 | $163 |
| Allopurinol | 16 | $147 |
| ClopidogrelClopidogrel Bisulfate | 16 | $145 |
| Simvastatin | 17 | $121 |
| Ropinirole Hcl | 13 | $109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,183 | $31,28045 claims |
| Fresenius USA Marketing, Inc.Velphoro | $242 | $16,99511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,341 nephrology providers in California.
Other nephrology in San Dimas
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.